Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fiskars appoints Tuomas Hyyryläinen as Chief Growth Officer and member of the Fiskars Group Leadership Team

Fiskars CorporationStock Exchange ReleaseJune 12, 2018 at 9:30 EEST Fiskars appoints Tuomas Hyyryläinen as Chief Growth Officer and member of the Fiskars Group Leadership Team Fiskars has appointed Tuomas Hyyryläinen as Chief Growth Officer and member of the Fiskars Group Leadership Team (FGLT) from September 1, 2018. He will report to Fiskars President and CEO Jaana Tuominen. ″During the past years Fiskars has focused on structural changes, building common platforms and creating unified ways of working. As this work will continue, the existing foundation allows us to shift our

Camurus and Medison enter into commercialization agreement for CAM2038 in Israel

Lund, Sweden — 12 June 2018 — Camurus AB (Nasdaq STO, CAMX) and Medison Pharma Ltd. announced today an exclusive agreement to commercialize CAM2038 weekly and monthly buprenorphine depot injections in Israel. CAM2038 is being developed for the treatment of adults with moderate to severe opioid dependence, representing a huge global healthcare problem. Under terms of the agreement, Medison will have the exclusive right to commercialize CAM2038 in all indications, including opioid dependence and chronic pain, in Israel. Medison will also be responsible for obtaining regulatory approval for

Update: lanabecestat Phase III Alzheimer's trials

This announcement contains inside information 12 June 2018 07:00 BST Update on Phase III clinical trials of lanabecestat for Alzheimer's disease Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring

Capital markets day, 12 June 2018: Ferronordic presents its work with digitalization, employees and compliance

Press ReleaseStockholm, 12 June 2018Today, 12 June 2018, Ferronordic Machines AB (”Ferronordic”) arranges a capital markets day for analysts, investors and media to highlight how the company conducts a sustainable and increasingly digitalized business in Russia. Lars Corneliusson, CEO, starts the day with a general overview of the Russian market, the company’s operations and its aftermarket focus. Anders Blomqvist, CFO, describes the company’s financial targets, efficient use of capital and profitability development. Then follows a presentation of the four main themes of the day.

Targovax hosts conference call 12 June 2018

Oslo, Norway, 12 June 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing and commercializing immune activating oncology therapies to target, primarily, treatment resistant solid tumors, today hosts a conference call to give an update to its clinical development strategy.For reference, please see the press release from 11 June 2018 here .The conference call will include a presentation from the

Starbreeze, Skybound Entertainment and 505 Games reveal November 2018 release for Overkill’s the Walking Dead

Pre-orders Available June 12 for Launch on Nov. 6 in the Americas and Nov. 8 Globally on PlayStation®4, Xbox One and Windows PC See the Upcoming Co-op Shooter in Action for the First Time in Debut Gameplay Trailer MEDIA BLAST - STOCKHOLM  – June 12, 2018 – Starbreeze, Skybound Entertainment and 505 Games have released the first official gameplay trailer for OVERKILL’s The Walking Dead, the upcoming cooperative multiplayer FPS from developer OVERKILL – A Starbreeze Studio. The video also reveals the game is expected to launch on the PlayStation®4 computer entertainment

Automotive company commits to Hexagon Composites as supplier to fuel-cell electric vehicles

Hexagon Composites will supply compressed hydrogen tanks for serial production of fuel cell electric vehicles (FCEV) to be launched by an automotive OEM.Hexagon is currently developing the tanks to support anticipated production activities as early as 2020. Production is planned to run for at least five years. Hexagon estimates the combined value for development and serial production to be in the range of USD 120 to 150 million (approximately NOK 1.0 billion to 1.2 billion)."This is a strategically important customer contract fulfilment for Hexagon and the growing FCEV industry. Hexagon

Nordic Nanovector Announces Betalutin® has been granted Fast Track designation in the US for Follicular Lymphoma

Oslo, Norway, 12 June 2018 Nordic Nanovector ASA (OSE: NANO) announces that the US Food & Drug Administration (FDA) has granted Fast Track designation to Betalutin® (177Lu-lilotomab satetraxetan) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies. Lisa Rojkjaer MD, Nordic Nanovector CMO, commented: “We are pleased to have been granted Fast Track designation for Betalutin®. This designation is based on the promising safety and preliminary efficacy data in patients with relapsed/refractory indolent non-Hodgkin’s

Elekta Nomination Committee’s proposed Board of Directors for the 2018 Annual General Meeting

STOCKHOLM, June 12, 2018 – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2018 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Annika Espander Jansson, Caroline Leksell Cooke, Johan Malmquist, Tomas Puusepp, Wolfgang Reim, Jan Secher, Birgitta Stymne Göransson and elect Cecilia Wikström. Luciano Cattani has declined re-election. Cecilia Wikström has broad experience and knowledge of international – and especially European – business and social issues. She has been a Member of the European

UNITED THERAPEUTICS AND XVIVO PERFUSION ANNOUNCE COLLABORATION TO REDUCE ORGAN SHORTAGE THROUGH EXPANSION OF ORGAN EVALUATION SERVICE

Silver Spring, MD and Englewood, CO, June 12, 2018: United Therapeutics Corporation (Nasdaq: UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), today announced that the use of XVIVO’s ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics’ public benefit corporation subsidiary Lung Biotechnology PBC. “I am excited about trying to make more life-saving use of donated lungs via XVIVO Perfusion’s pioneering technology,” said Martine Rothblatt, Ph.

Changes in Investor Relations at Ambea

Jacob Persson will be new Head of Investor Relations at Ambea. Louise Tjeder, has been the IR-manager since 2016 will leave the company during the autumn. Louise has played an important role in Ambea's IPO-process and in establishing stock market routines within Ambea.Jacob Persson, has been at Ambea for two years and worked with acquisitions, business development and as internal project manager during the IPO-process. He will now be responsible for IR. - I would like to thank Louise for her important contribution and welcome Jacob in his new role says, Fredrik Gren, CEO Ambea.

Multiconsult ASA – repurchase of own shares completed

On 11 June 2018, Multiconsult ASA ("Multiconsult") purchased 11 374 own shares in relation to the annual management bonus compensation programme. The shares were purchased at an average price of NOK 64.78 per share. The shares were purchased on Oslo Børs in accordance with the share repurchase announced on 11 June 2018.Following this transaction Multiconsult holds 11 430 of its own shares. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.For further information, please contact:Investor relations:   Mirza

FundedByMe launches its first Polish crowdfunding campaign

FundedByMe has had an office in Poland since April this year. This summer they are launching their first Polish crowdfunding case, Blinkee.city. The app has been up and running in 8 Polish cities as well as in Budapest, now they want to offer scooters for rent in Stockholm.FundedByMe has had an office in Poland since April this year. This summer they are launching their first Polish crowdfunding case, Blinkee.city. The app has been up and running in 8 Polish cities as well as in Budapest, now they want to offer scooters for rent in Stockholm. — We believe that the Blinkee team is world

Nordic Entertainment Group acquires rights to IHF and EHF handball competitions

· NENT Group secures exclusive Nordic media rights to IHF World Handball Championship until 2025 and EHF European Handball Championship (EHF EURO) until 2026 · NENT Group extends rights to EHF Champions League, European Handball League and EHF Cup until 2023 · NENT Group is undisputed Nordic home of handball Nordic Entertainment Group (NENT Group) has secured the exclusive Nordic media rights to the IHF World Handball Championship until 2025 and the EHF European Handball Championship (EHF EURO) until 2026. NENT Group has also extended the rights to the EHF Champions League,

More gas buses for Helsinki Metropolitan Area public transport

The number of gas-fueled buses in the Helsinki Metropolitan Area will increase when Scania delivers two new gas buses to the bus company Helsingin Bussiliikenne at the beginning of 2019. New-generation gas buses are the most cost-effective way to reduce carbon dioxide and local emissions from urban transport. In the future there will be even more alternatives available for cleaner transport as the EU will set the minimum targets for the public sector’s clean vehicles procurement.Two new gas buses will start service in Helsinki Metropolitan Area public transport at the beginning of 2019. Gas

Multiple lasers could be replaced by a single microcomb

Every time we send an e-mail, a tweet, or stream a video, we rely on laser light to transfer digital information over a complex network of optical fibers. Dozens of high-performance lasers are needed to fill up the bandwidth and to squeeze in an increasing amount of digital data. Researchers have now shown that all these lasers can be replaced by a single device called a microcomb. A microcomb is an optical device that generates very sharp and equidistant frequency lines in a tiny microphotonic chip. This technology was developed about a decade ago and is now reaching a maturity level

SEK 7 billion into equity funds in May

In May, investment funds recorded a total net inflow of SEK 7.2 billion. Net deposits were primarily made in equity funds and balanced funds, whereas hedge funds and short term fixed income funds recorded net withdrawals. The total fund assets in Sweden increased during the month by SEK 38 billion and amounted at the end of May to the new record-high level of SEK 4 233 billion.Investment funds recorded a total net inflow of SEK 7.2 billion in May. Equity funds had net deposits of SEK 7 billion and balanced funds had net deposits of SEK 3.7 billion. Hedge funds and short term fixed income

Securitas completes acquisition of Kratos Public Safety and Security division

Regulatory authorities have approved Securitas’ acquisition of the division Kratos Public Safety and Security from Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS).As disclosed on February 28, Securitas has agreed to acquire Kratos Public Safety and Security (KPSS), a top 10 system integrator in the United States. The purchase price is approximately MSEK 600 (MUSD 69) on a cash and debt-free basis. The acquisition is expected to be neutral to Securitas earnings per share in 2018 and 2019, and accretive as of 2020. The operation has annual sales of approximately MSEK 1 175 (MUSD 135)

Targovax strengthens focus on ONCOS oncolytic virus development program

Recent clinical data is driving increased interest in the industry for oncolytic viruses as an emerging class of cancer therapeutics Development of Targovax lead product, ONCOS-102, to be prioritized in mesothelioma as launch indication as well as checkpoint inhibitor combinations in cold tumors---------------------------------------------------------------------- Conference call The company will host a conference call which will include a Q&A session. CEO Øystein Soug, CMO Magnus Jäderberg and CFO Erik Digman Wiklund will host the conference call. Call in details can be found

BULLETIN FROM BEWI GROUP AB (PUBL):S ANNUAL GENERAL MEETING 2018

PRESS RELEASE FROM BEWI GROUP AB (PUBL) June 11, 2018 BEWi Group AB (publ)’s Annual General Meeting took place on Monday 11 June 2018 at the company’s Head Office in Solna.Adoption of the income statement and the balance sheet, appropriation of profits and discharge from liability The Annual General Meeting (the “Meeting”) approved the income statement and the balance sheet for the parent company and the Group for the financial year 2017. In accordance with the proposal of the Board of Directors, the Meeting further resolved not to pay dividend for the financial year 2017. The

Ossur Hf : Transactions in relation to share buyback program

Announcement no. 39/2018Reykjavik, 11 June 2018  Transactions in relation to share buyback program On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 28 February 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share

Outokumpu will issue EUR 250 million bond

Outokumpu OyjStock exchange releaseJune 11, 2018 at 7.00 pm EEST Outokumpu will issue EUR 250 million bond Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan or Singapore, or any other jurisdiction in which the distribution or release would be unlawful. Outokumpu will issue a EUR 250 million senior secured bond and at the same time, confirms the fulfilment of the new financing condition, announced on May 9, 2018, regarding the call of all fixed rate notes due 2021 (ISIN FI4000210646, OUTJ072521)

Alexion holds 99.8 percent of the shares in Wilson Therapeutics after the expiry of the extended acceptance period

THE OFFER REFERRED TO IN THIS PRESS RELEASE IS NOT BEING MADE, EITHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER, ACCORDING TO LEGISLATION AND REGULATIONS IN SUCH JURISDICTION, WOULD BE PROHIBITED BY APPLICABLE LAW. THE OFFER IS NOT BEING MADE TO (NOR WILL TENDER OF SHARES BE ACCEPTED FROM) PERSONS IN THESE COUNTRIES OR PERSONS IN ANY OTHER JURISDICTIONS WHERE TENDER OF SHARES WOULD DEMAND FURTHER DOCUMENTATION, FILINGS OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED PURSUANT TO SWEDISH LAW.

There are no items matching the current filter
There are no more items matching the current filter
Back to top